---
title: "Heron Shareholders Approve Directors, Incentive Plans, Tax Measures"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289958725.md"
description: "Heron Therapeutics shareholders approved key measures at the June 11, 2026 annual meeting, including electing seven directors, ratifying the independent auditor, and endorsing executive compensation. Investors also expanded equity incentive and employee stock purchase plans by significant margins and ratified a nonbinding Tax Benefits Preservation Plan to protect tax assets. The company remains focused on biopharmaceutical development, though analyst sentiment is mixed with a 'Buy' rating from analysts but a 'Neutral' AI assessment citing weak financials."
datetime: "2026-06-16T19:17:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289958725.md)
  - [en](https://longbridge.com/en/news/289958725.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289958725.md)
---

# Heron Shareholders Approve Directors, Incentive Plans, Tax Measures

### Claim 55% Off TipRanks

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

An update from Heron Therapeutics ( (HRTX) ) is now available.

At its 2026 Annual Meeting of Stockholders held on June 11, 2026, Heron Therapeutics’ shareholders elected seven directors to serve until the 2027 meeting and ratified Withum Smith+Brown, PC as the independent registered public accounting firm for the 2026 fiscal year. Investors also approved on an advisory basis executive compensation for 2025, endorsing management’s pay structure amid the company’s ongoing efforts to execute its strategy.

Shareholders voted to expand the 2007 Equity Incentive Plan by 16,560,000 shares and the 1997 Employee Stock Purchase Plan by 10,000,000 shares, significantly increasing the pool of stock available for employee and executive incentives. They further ratified, on a nonbinding advisory basis, the Tax Benefits Preservation Plan, signaling support for measures aimed at protecting the company’s tax assets and providing Heron with additional tools to manage dilution, retain talent, and preserve financial flexibility.

The most recent analyst rating on (HRTX) stock is a Buy  
with a $2.00 price target.  
To see the full list of analyst forecasts on Heron Therapeutics stock,  
see the HRTX Stock Forecast page.

**Spark’s Take on HRTX Stock**

According to Spark, TipRanks’ AI Analyst, HRTX is a Neutral.

The score is weighed down primarily by weak financial quality (negative cash flow, negative margins, revenue contraction, and very high leverage with a thin equity cushion) and bearish technicals (price below key moving averages with negative MACD). These are partially offset by a more constructive earnings-call outlook with reaffirmed 2026 guidance and cited product-level demand momentum, while valuation signals are limited because the company remains loss-making and has no dividend yield.

To see Spark’s full report on HRTX stock,  
click here.

**More about Heron Therapeutics**

Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical therapies. The company operates in the healthcare sector, with a business model that depends on effective capital markets access and equity-based compensation programs to attract and retain key talent in a competitive life sciences industry.

**Average Trading Volume:** 2,882,810

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $75.73M

Find detailed analytics on HRTX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [HRTX.US](https://longbridge.com/en/quote/HRTX.US.md)

## Related News & Research

- [HRTX: Q2 2026 net revenue grew 9% sequentially, but full-year guidance was withdrawn amid legal uncertainty](https://longbridge.com/en/news/295405345.md)
- [Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday](https://longbridge.com/en/news/294710967.md)
- [Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook](https://longbridge.com/en/news/295404922.md)
- [How can we minimize taxes in retirement with a -2-](https://longbridge.com/en/news/295306916.md)
- [How can we minimize taxes in retirement with a -2-](https://longbridge.com/en/news/295400194.md)